A-shares open · 港股交易中 Quotes 行情 · 28 Sep 11:16 CST
28 Sep 2026 · 11:16 CST Terminal Access 终端入口 →
300452.SZ深圳证券交易所 · 创业板 ChiNext

Anhui Sunhere Pharmaceutical Excipients 山河药辅

Chemical Pharmaceuticals 化学制药
¥13.12¥0.00 · +0.00%Delayed 行情延迟 · 28 Sep 2026 · 11:15 CST · CNY
Open 开盘
¥13.20
High 最高
¥13.27
Low 最低
¥13.04
Prev Close 昨收
¥13.12
Volume 成交量
196.8万股
Turnover 成交额
¥2,594.3万
Mkt Cap 总市值
¥31亿
P/E 市盈率
17.1×
Recent Activity 近期动态All Filings 全部公告 →

6 significant filings since 31 May 2026: 4 on share issue and 2 on dividend. The latest, on 1 Jul 2026: 关于2026年第二季度可转债转股情况的公告.
自 31 May 2026 起有 6 份重大公告:share issue 4 份、dividend 2 份。最新一份(1 Jul 2026):关于2026年第二季度可转债转股情况的公告。

Price History 价格走势

22 trading days 个交易日 · High 最高 ¥13.28 · Low 最低 ¥12.55
12.6012.7012.8012.9013.0013.1013.20
Volume 成交量
718.3万
26 Aug02 Sep09 Sep17 Sep24 Sep
Last Twelve Months 近十二个月
1 report from 1 broker · 1 unrated 1 家券商 1 份研报,1 份无评级
Reports Share Market
Buy 买入 0 — 70.7%
Outperform 增持 0 — 28.6%
Neutral 中性 0 — 0.7%
Underperform 减持 0 — 0.0%
Sell 卖出 0 — 0.0%

The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平:同期 99.3% 的评级为买入或跑赢。

Rating Changes 评级变动
3 up · 1 down in all reports held 全部研报中上调 3 次,下调 1 次
Date 日期Broker 券商Analyst 分析师From 原评级To 新评级
20 Nov 2023国元证券马云涛Outperform 增持▲Buy 买入
1 Nov 2022西南证券杜向阳Outperform 增持▲Buy 买入
15 Aug 2022西南证券杜向阳Buy 买入▼Outperform 增持
25 Dec 2017东兴证券张金洋,缪牧一Outperform 增持▲Buy 买入

Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。

Current Coverage 当前覆盖
Broker 券商Analyst 分析师Latest Rating 最新评级Date 日期Reports 研报Target 目标价
信达证券唐爱金Unrated6 May 20261—

Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 1 report. 每行为该券商近十二个月的最新研报;1 份中 0 份给出目标价。

Coverage by Quarter 覆盖变化
2 23Q4
0 24Q1
1 24Q2
0 24Q3
0 24Q4
0 25Q1
0 25Q2
0 25Q3
0 25Q4
0 26Q1
1 26Q2
0 26Q3

Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数,最近一个季度尚未结束。